Upadacitinib Looks Promising for Patients With Giant Cell Ar

The phase 3 SELECT-GCA study evaluated the efficacy and safety of upadacitinib in patients 50 years of age and older with GCA.

Related Keywords

Gasthuisberg , Region Flamande , Belgium , Leuven , Daniel Blockmans , University Hospitals Gasthuisberg , General Internal Medicine ,